Biblio
Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024.
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica. 2024.
Do MYC rearrangements Matter in HIV-Associated Large B Cell Lymphomas? "EUROMYC" Study (a European retrospective study). Blood Adv. 2024.
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey. Int J Antimicrob Agents. 2023:106806.
COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation. Hematol Oncol. 2023.
MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. Int J Antimicrob Agents. 2023:106952.
COVID-19 and Hairy-Cell Leukemia: An EPICOVIDEHA Survey. Blood Adv. 2022.